

MIND OVER MATER: A REVIEW OF SUPPORTIVE CARE FOR PRIMARY AND SECONDARY BRAIN MALIGNANCIES	Presented by: Haley Peterson, PharmD PGY2 Oncology Resident Haley.Peterson@hci.utah.edu
PERITUMORAL EDEMA	SEIZURES
TREATMENT <ul style="list-style-type: none"> • Corticosteroids <ul style="list-style-type: none"> ○ Antiedema effect due to reduction of permeability of tumor capillaries and suppression of VEGF production and increased expression of tight junction proteins ○ Dexamethasone commonly used ○ Dosing considerations: <ul style="list-style-type: none"> ▪ Minimum effective doses should be used ▪ Night-time doses should be avoided ▪ Taper quickly and as tolerated by patient ▪ Can do once or twice daily dosing • Bevacizumab <ul style="list-style-type: none"> ○ Anti-VEGF monoclonal antibody ○ Can be used in refractory cerebral edema or as a steroid sparing agent ○ Common side effect is hypertension 	TREATMENT <ul style="list-style-type: none"> • Prophylactic anticonvulsants are not recommended • Start treatment after patient has a seizure • No antiepileptic drug (AED) has been found to be superior, and choice of AED should be patient specific • Overall recommended to choose a medication that is a non-enzyme inducer, such as – <ul style="list-style-type: none"> ○ Levetiracetam ○ Lacosamide ○ Lamotrigine ○ Valproic acid • At the end of life, seizures prevalence can increase, and management can be hindered by swallowing difficulties or impaired consciousness. Some non-oral options include – <ul style="list-style-type: none"> ○ Buccal clonazepam ○ Intranasal midazolam
VENOUS THROMBOEMBOLISM	ENDOCRINOPATHIES
<ul style="list-style-type: none"> • Patients with CNS tumors have a higher risk of developing venous thromboembolism (VTE) compared to other types of cancer TREATMENT <ul style="list-style-type: none"> • Not recommended to start anticoagulation as primary prevention • Start anticoagulation once diagnosis of VTE has been confirmed • Many studies examining efficacy and safety of direct oral anticoagulants (DOACs) in patients with cancer either excluded patients with brain malignancies or those patients were underrepresented • Due to this, guidelines recommended low molecular weight heparin (LMWH) as treatment for VTE in patients with brain malignancies • However, new studies have been published demonstrating similar efficacy and safety of DOACs in patients with and without brain malignancies 	<ul style="list-style-type: none"> • Hypothalamic-pituitary axis complications can result from – <ul style="list-style-type: none"> ○ Disease at presentation ○ Following surgical intervention ○ Following radiation therapy • The time to symptoms varies, but can happen as early as one year after radiation therapy • A 2011 systematic review showed that hypopituitarism pooled prevalence was 66% ANTIDIURETIC HORMONE (ADH) DEFICIENCY <ul style="list-style-type: none"> • Also called diabetes insipidus • ADH causes the kidneys to release less water -> decreasing the amount of urine produced • Treatment – desmopressin <ul style="list-style-type: none"> ○ Synthetic analog of antidiuretic hormone ADRENOCORTICOTROPIC HORMONE (ACTH) DEFICIENCY <ul style="list-style-type: none"> • Leads to insufficient production of cortisol • Symptoms including fatigue, weight loss, hypotension • Treatment – hydrocortisone <ul style="list-style-type: none"> ○ Give 2/3 of the dose in the morning and 1/3 of the dose in the afternoon to mimic normal physiology